诚达药业(301201) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥102,199,584.64, a decrease of 5.91% compared to ¥108,619,193.47 in the same period last year[5] - Net profit attributable to shareholders was ¥19,644,988.66, down 25.10% from ¥26,229,854.86 year-on-year[5] - Basic and diluted earnings per share decreased by 31.33% to ¥0.2032 from ¥0.2959 in the same period last year[5] - The company reported a net profit margin decline due to increased costs, impacting overall profitability[22] - The net profit for the first quarter of 2023 was CNY 19,620,310.26, a decrease of 25.2% compared to CNY 26,213,014.63 in the same period last year[23] - Operating profit for the first quarter was CNY 23,929,664.90, down from CNY 30,931,613.34, reflecting a decline of 22.6% year-over-year[23] - Total comprehensive income for the first quarter was CNY 19,620,310.26, compared to CNY 26,213,014.63, indicating a decline of 25.2%[24] Cash Flow and Investments - The net cash flow from operating activities increased significantly by 679.23%, reaching ¥68,175,884.92 compared to ¥8,749,113.60 in the previous year[5] - Cash flow from operating activities showed a significant increase to CNY 68,175,884.92, compared to CNY 8,749,113.60 in the previous year, representing a growth of 678.5%[27] - Cash flow from investing activities generated a net inflow of CNY 739,885,063.10, a substantial improvement from a net outflow of CNY 843,462,046.94 in the same period last year[27] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,355,840,310.21, reflecting a 1.46% increase from ¥2,321,895,635.83 at the end of the previous year[5] - Total liabilities rose to ¥119,950,037.07, up from ¥105,811,942.95 at the beginning of the year[20] - Shareholders' equity totaled ¥2,235,890,273.14, an increase from ¥2,216,083,692.88 at the start of the year[20] - Cash and cash equivalents increased by 133.77% to ¥1,412,968,938.23, primarily due to the redemption of structured deposits[10] - Cash and cash equivalents at the end of Q1 2023 were ¥1,412,968,938.23, compared to ¥604,430,176.14 at the beginning of the year[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,723[12] - The largest shareholder, Ge Jianli, holds 27.17% of the shares, totaling 26,269,600 shares[12] - The second-largest shareholder, Huang Honglin, owns 12.62% of the shares, amounting to 12,205,000 shares[12] - The top ten shareholders collectively hold significant stakes, with the third-largest being Shenzhen Shengtai Investment Management Co., holding 11.24% or 10,869,900 shares[12] - The company has a total of 0 preferred shareholders with voting rights at the end of the reporting period[12] - The total number of shares held by the top ten unrestricted shareholders is 10,869,900 shares[13] - The company has a total of 26,269,600 shares under lock-up for Ge Jianli, which will be released on July 20, 2025[15] - The company has 15,500,000 shares under lock-up for Shenzhen Shengtai Investment Management, which were released on January 20, 2023[15] - The total number of shares held by the top ten shareholders with restricted shares is 26,269,600 shares[15] - The company has a total of 3,800,000 shares under lock-up for Jiaxing Maiter Equity Investment Partnership, which will be released on January 20, 2023[15] Operating Costs and Expenses - Total operating costs increased to ¥88,542,464.12, up 11.5% from ¥79,398,196.77 in Q1 2022[22] - Operating costs included ¥64,935,683.33 in cost of goods sold, which rose significantly from ¥52,567,074.55 year-over-year[22] - The company reported a decrease in sales expenses by 39.18%, amounting to ¥1,008,413.89, due to reduced commissions and freight costs[9] - Research and development expenses were CNY 4,757,398.07, slightly down from CNY 4,979,563.71, indicating a decrease of 4.4%[23] Other Notable Information - The company experienced a 220.82% increase in prepayments, totaling ¥18,114,750.67, attributed to higher material prepayments[10] - The company’s contract liabilities increased by 86.03% to ¥11,500,872.18, indicating a rise in advance payments received[10] - The company did not report any new product launches or significant market expansion strategies during this quarter[28]